ArticleHaematologica2026
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.International journal of clinical oncology · 2026Article
- Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma.Haematologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard-of-care therapy with frontline DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, rituximab). However, treatment strategies following relapse after DA-EPOCH-R are not well defined. We, therefore, performed a retrospective review of PMBCL patients with relapsed/refractory (R/R) disease after frontline DA-EPOCH-R to obtain better insight into outcomes with salvage therapy and autologous stem cell transplant (SCT). Our cohort consisted of 107 patients with R/R PMBCL. Ninety patients qualified for the intention-to-treat salvage therapy analysis. With a median follow up of 48.9 months in the salvage therapy analysis, the median progression-free survival was 5.4 months (95% confidence interval [95% CI]: 2.3 months-not reached) with a 5-year overall survival rate of 78% (95% CI: 69-88). Compared to relapsed patients (relapsing >6 months after frontline DA-EPOCH-R, N=23), refractory patients (relapsing <6 months after frontline DA-EPOCH-R, N=67) had an inferior overall response rate (48% vs. 83%), complete remission rate (19% vs. 44%), and 2-year progression-free survival rate (30% vs. 69%) with initial salvage therapy. Forty-eight patients (53%) underwent autologous SCT after salvage therapy with estimated 5-year progression-free and overall survival rates of 85% (95% CI: 75-96) and 88% (95% CI: 79-99), respectively. There were no relapses among 29 patients in complete remission prior to autologous SCT. In conclusion, this analysis is the largest review of R/R PMBCL to date and demonstrates unfavorable outcomes for patients with refractory disease after frontline DA-EPOCH-R chemotherapy. Patients able to undergo autologous SCT, especially those in complete remission prior to the transplant, had excellent outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.